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ABSTRACT
Patients with psoriasis are at an increased risk for depression. Despite this risk, many
dermatology care providers do not screen for depression in practice, including providers at the
target practice for this project. This evidence-based practice pilot project was purposed to
increase dermatology providers’ assessment of depression in patients with psoriasis. This project
involved implementing a depression screening protocol at one private dermatology practice and
educating providers on the use of the protocol including the embedded depression screening tool,
the Patient Health Questionnaire-9. The project leader used a quasi-experimental design and
collected data utilizing retrospective chart reviews completed pre- and post-intervention. The
measurable outcomes for this project included the number of depression screenings documented
versus the number of patients with psoriasis seen during a 30-day period pre- and postintervention. This project revealed both clinical and statistical improvement of depression
screening post-intervention supporting that provider assessment of depression in patients with
psoriasis was enhanced with the implementation of a screening protocol. The results of this
project have important implications for enhancing depression screening for patients with
psoriasis in dermatology care settings.
Keywords: Psoriasis, depression, suicidality, screening protocol, dermatology, Patient
Health Questionnaire-9
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Dedication
This scholarly project is dedicated to every person who has ever experienced depression
or has been impacted by suicide in some way, shape, or form – to every mother, father,
grandparent, sibling, spouse or significant other, friend, coworker, or child who has lost a loved
one to suicide. Depression is a disorder. It is not something to be taken lightly and certainly not
something a person can simply just get over. My hope is that this project will help to shed light
on the importance of addressing depression and other mental health disorders for all ages and all
patient populations.
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Introduction
Psoriasis (PSO) is a common chronic inflammatory skin condition characterized by skin
lesions that can cause pain, itching, burning, and irritation (Menter & Ryan, 2017). There are
varying degrees of severity in PSO, which can be further complicated by non-cutaneous
comorbidities such as inflammatory arthritis and cardio-metabolic disorders (Singh, Taylor,
Kornmehl, & Armstrong, 2017). The burden of PSO as a disease goes far beyond dermatologic
considerations. The physical, psychosocial, and financial burden of PSO can have a profound
negative impact on a patient’s quality of life (QoL) and place the patient at a significant risk for
psychological conditions such as depression (Singh et al., 2017).
Though many dermatology practitioners acknowledge the risk of depression in patients
with dermatologic diseases, it is uncertain how often dermatologists screen at-risk patients for
secondary psychiatric disorders (McDonald, Shelley, & Jafferany, 2018). Clinical practice
guidelines and expert recommendations on treating and managing PSO acknowledge the
importance of addressing comprehensive care for this patient population including the
assessment of depression (Burden et al., 2010). This evidence-based practice (EBP) pilot project
provided a depression screening protocol and education on the use of the protocol to providers in
a dermatology clinic in efforts to enhance the quality of care delivered to patients with PSO.
Background
Background on Psoriasis
Epidemiology. PSO is one of the most common chronic dermatologic conditions and
affects more than 125 million people worldwide (Menter & Ryan, 2017). It is estimated that 7.4
million adults in the United States (U.S.) have PSO (Rachakonda, Schupp, & Armstrong, 2014).
The reported incidence is approximately 59.9 per 100,000 people per year (Menter & Ryan,
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2017). In adults, men appear to have a higher incidence of the disease than women, and the
prevalence of PSO is lower in non-Caucasians (Menter & Ryan, 2017).
Characteristics and risk factors. There are many different types of PSO. The most
common type is plaque-type psoriasis or psoriasis vulgaris, which accounts for 90% of the cases
of PSO (Menter & Ryan, 2017). PSO can occur on any part of the body but commonly affects
the scalp, trunk, and extensor surfaces which are often visible parts of the body (Menter & Ryan,
2017). Some notable risk factors for PSO include family history, infection, certain medications,
stress, smoking, alcohol use, sunburn, and trauma (Menter & Ryan, 2017).
Physical impact. Plaque psoriasis generally causes well-demarcated symmetrical
erythematous plaques with variable adherent scaling and thickness typically involving elbows,
knees, trunk, scalp, sacrum, buttocks, and genitals (Menter & Ryan, 2017). Many people with
chronic PSO will report intermittent disease exacerbations with pain, itching, and burning
(Menter & Ryan, 2017). Though predominately affecting the skin, PSO can have a greater health
impact than what can be seen by the human eye. Due to the nature of systemic inflammation,
PSO is associated with an increased prevalence of cardio-metabolic diseases such as
atherosclerotic cardiovascular disease, diabetes, obesity, and future vascular events (Menter &
Ryan, 2017). In addition to these serious comorbidities, psoriatic arthritis (PsA) occurs in up to
30% of people with PSO and can cause significant disability (Longo, Ritchlin, Colbert, &
Gladman, 2017).
Psychosocial impact. PSO by nature affects the appearances of individuals and as
mentioned, is often present on parts of the body that are visible to others (Nazik, Nazik, & Gul,
2017). Many patients with PSO fear stigmatization because of their disease and report that their
condition negatively impacts their body image and sexuality (Hrehorów, Salomon, Matusiak,
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Reich, & Szepietowski, 2012; Nazik et al., 2017). Some of the most common feelings of
stigmatization described by patients are the anticipation of rejection and feelings of guilt and
shame (Hrehorów et al., 2012). Many people also report that their PSO affects their ability to
perform daily activities (Nazik et al., 2017).
Financial impact. An additional burden of PSO is the financial impact of patient costs
associated with the disease. Successful treatment and management of PSO is often associated
with increased healthcare resource utilization and increased patient costs (Yu et al., 2009).
Consequently, on average, a patient with PSO will spend $11,498 over a lifetime for the relief of
symptoms (Brezinski, Dhillon, & Armstrong, 2015). Newer long-term medications on the market
for PSO can cost patients as much as thousands of dollars each month. With respect to the
potential physical, emotional, psychosocial, and financial impact of PSO, there are comparable
degrees of disability caused by PSO to other chronic diseases such as diabetes, heart disease, and
cancer (Burden et al., 2010).
Background on Depression
Epidemiology and disease definition. In the U.S., major depression is one of the most
common psychological disorders (National Institute of Mental Health [NIMH], n.d.). It is
estimated that 16.1 million adults ages 18 and older had at least one major depressive episode in
the past year, accounting for 6.7% of adults in the U.S. (NIMH, n.d.). According to the
diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders V (DSM5), major depressive disorder (MDD) consists of five or more specific symptoms that must be
present for at least two weeks and signal a change from previous functioning (American
Psychiatric Association [APA], 2013). Some of these symptoms include a depressed mood,
diminished interest or pleasure in activities, significant unintentional weight loss or weight gain,
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a decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation, fatigue or
loss of energy, feelings of worthlessness, diminished concentration, and recurrent thoughts of
death (APA, 2013).
Impact of depression as a disease. In the U.S. and worldwide, depression has indirect
and direct effects on morbidity and mortality (Smithson & Pignone, 2017). Significant available
research demonstrates the negative effects of depression on an individual’s quality of life
(Sivertsen, Bjørkløf, Engedal, Selbæk, & Helvik, 2015). Furthermore, MDD accounted for an
economic burden of more than $210 billion in 2010 alone (Greenberg, Fournier, Sisitsky, Pike,
& Kessler, 2015). In efforts to reduce morbidity, mortality, and healthcare costs associated with
depression, healthcare providers play an important role in identifying patients with depression
and those at risk for mental health disorders.
Depression and psoriasis. The risk of depression amongst patients with PSO is welldocumented; however, the exact relationship between the two is still unknown (Singh et al.,
2017). According to Dowlatshahi, Wakkee, Arens, and Nijsten (2014), patients with PSO are 1.5
times more likely to have depression and more than 4 times as likely to use antidepressants as
patients without PSO. A recent meta-analysis study reports that patients with PSO have a
significantly higher likelihood of suicidal ideation, suicide attempts, and completed suicides
(Singh et al., 2017). Patients with PSO who suffer from PsA have been found to be at an even
greater risk for depression than those without the comorbidity (McDonough, 2014). The
knowledge of the risk of depression and suicidality in patients with PSO points to a need for
appropriate screening methods in practice for early identification and treatment of depression for
this patient population.
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Background on Depression Screening
Use of screening. Healthcare providers play an important role in assessing their patients
for depression. Depression screening is not a new concept, and a growing body of literature
supports the benefits of screening in combination with resources for disease management in the
treatment of depression (Smithson & Pignone, 2017). Screening patients with chronic disease for
depression is not a new consideration either and is well documented in patients with other
chronic diseases such as chronic obstructive pulmonary disease and congestive heart failure
(Julian et al., 2009; Buckley, 2015).
Currently, the U.S. Preventative Service Task Force (USPSTF) recommends depression
screening for all adults and especially for those adults with chronic disease (USPSTF, 2016).
While primary care offices are generally the target areas for systematic depression screening,
rates of depression screening in primary care remain low (Akincigil & Matthews, 2017).
Specialty care providers must not assume depression is being addressed in primary care and
should take this into consideration when caring for at-risk patients.
Challenges with screening. Though depression screening tools offer many benefits,
barriers to utilizing depression screenings in practice exist. Some cited barriers in utilizing
depression screenings are time constraints, competing demands, and prior knowledge about the
patient’s depression status (Fuchs et al., 2015). Knowledge regarding the barriers in using
depression screening tools in dermatology is limited (McDonald et al., 2018). Potential barriers
may include a lack of clear guidelines, lack of time, or perception that secondary psychiatric
disorders, such as depression, are outside of the dermatology domain (McDonald et al., 2018).
This EBP project aims to utilize a protocol that incorporates an already validated depression
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screening tool that can be delivered quickly to minimize barriers to the implementation of
depression screening at the target dermatology practice.
Opportunities for the Project
There are many opportunities for this EBP project. Currently, depression screenings are
recognized for reimbursement by Medicare and some private insurances in primary care on an
annual basis (Savoy & O'Gurek, 2016). Codes for annual depression screenings generate
approximately $15-$18 per patient per year (Savoy & O'Gurek, 2016). With that being said,
specialty care providers, such as those in dermatology, currently have little financial incentive to
perform depression screening. This presents a problem as some patients are often only or at least
more frequently seen by specialty care providers, and depression screening in primary care
remains low (Akincigil & Matthews, 2017). This project may help to further demonstrate the
benefits and importance of depression screening for patients with chronic illnesses in specialty
care areas like patients with PSO in dermatology.
This EBP project may also help to improve the care delivered to patients with PSO at the
target dermatology practice. Though this project did not look specifically at patients who screen
positive for depression or how patients identified with depression were managed, providers who
utilize the depression screening protocol may identify practice patients who could benefit from
psychiatric services to promote overall health and could determine high-risk patients for
depression not otherwise recognized. This notion has implications for improving comprehensive
care and enhancing collaboration among healthcare specialties such as between dermatology,
psychiatry, and primary care services.
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Problem Statement
Though patients with PSO are at an increased risk for depression, many providers do not
screen this population for depression in practice, which may lead to failure in the recognition of
patients with depression requiring treatment.
Purpose of the Project
The purpose of this project is to increase dermatology providers’ assessment of
depression in patients with PSO. The significance of increasing depression screening in patients
with PSO is to allow for early recognition and referral for treatment of this common
psychological comorbidity.
Clinical Question
Will the implementation of a depression screening protocol and education on the use of
the protocol enhance provider assessment of depression in patients with PSO?
Population
The target population for this project was providers who care for patients with PSO at
one private dermatology practice.
Intervention
The primary intervention of this project was the implementation of a depression
screening protocol and education for the providers on the use of the protocol in practice.
Comparison
The project leader utilized chart reviews to compare depression screening prior to
(control group) and after the intervention (comparison group).
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Outcomes
The primary outcome was to increase provider assessment of depression in patients with
PSO by increasing the use of depression screening (PHQ-9) for this patient population.
Literature Review
Search Strategy
The project leader completed a search of CINAHL, PUBMED, JAMA, and ProQuest.
The keywords used for the literature review were psoriasis, depression, suicidality, screening,
depression protocol, PHQ-9, dermatology, comorbidities, self-esteem, body image,
stigmatization, and quality of life. All articles were limited based on those written in the last
fourteen years including a date range from 2004-2018. A majority of these articles were written
in the last six years. All articles gathered were in the English language, and a majority were fulltext articles with abstracts. The project leader reviewed over 70 abstracts for relevance and
selected 22 articles for the literature review.
Critical Appraisal
Evidence demonstrating the links between depression and PSO as well as the factors
contributing to the risk of depression in patients with PSO were important focuses of this review.
Besides why patients with PSO are at risk for depression, implications for depression screening
in dermatology are supported by available research including the depression screening tool
embedded in the protocol implemented for this project. The project leader reviewed and ranked
the literature according to strength utilizing a rating system for the hierarchy of evidence
(Melnyk & Fineout-Overholt, 2015). Out of the 22 studies included, there were two systematic
reviews and meta-analyses, nine controlled trials without randomization, six case-controls or
cohort studies, two single descriptive studies, and three expert opinions. Common limitations
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among the available research included small sample sizes for controlled trials, convenience
sampling, and non-randomization of subjects (see Appendix A for evidence table).
Psychosocial Factors Linked to the Risk of Depression in Patients with Psoriasis
Throughout the literature, research studies highlighted multiple psychosocial factors
contributing to the risk of depression in patients with PSO. The most common factors identified
throughout the review were self-esteem, body image, stigmatization, and perceived quality of
life. In the subsequent paragraphs these factors are discussed as they relate to patients with PSO.
Self-esteem and body image. As compared to patients without the disease, patients with
PSO have been found to have lower levels of satisfaction with body image and self-esteem
(Nazik et al., 2017). In particular, one study found that women with PSO report stronger beliefs
in the influence and importance of body image or physical appearance on self-worth (Wojtyna,
Lakuta, Marcinkiewicz, Bergler-Czop, & Brezezinska-Wcislo, 2016). Recognizing the
relationship between body image and depression, researchers have found that improving body
image in patients with PSO may contribute to the prevention of depression, especially in women
(Wojtyna et al., 2016).
Stigmatization. Patients with PSO may fear stigmatization because of the appearance of
their disease. Hawro et al. (2017) acknowledged PSO and stigmatization but aimed to more
clearly define the links among lesion distribution and severity of the disease to stigmatization.
They found that PSO lesions on the back of hands were related to higher levels of stigmatization
(Hawro et al., 2017). Furthermore, people who were not able to hide lesions by clothing reported
higher levels of stigmatization and women demonstrated a greater sensitivity to stigmatization
(Hawro et al., 2017). In this same study, the strongest predictor of QoL impairment was
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stigmatization suggesting that greater feelings of stigmatization result in reductions in an
individual’s reported QoL (Hawro et al., 2017).
Quality of life. PSO can be a debilitating skin disease with a significant negative impact
on health-related QoL. As previously cited, degrees of disability caused by PSO may be similar
to other chronic diseases such as diabetes, heart disease, and cancer (Burden et al., 2010). A
large portion of the burden on the QoL of patients with PSO centers on the psychosocial burden
of the disease. Throughout the literature search, multiple studies on PSO and QoL highlighted
psychosocial factors as having a negative impact on patients with PSO (Hawro et al., 2017;
Nazik et al., 2017; Wojtyna et al., 2016). For example, one study found that patients with PSO
have greater levels of loneliness and social isolation compared to those without the disease
translating into reductions in reported QoL (Kouris et al., 2016). Acknowledging decreased QoL
reported in patients with PSO, Korman, Zhao, Pike, and Roberts (2016) further studied the
relationship among severity of PSO and QoL and found that patients with more severe disease
experienced greater reductions in reported QoL.
Factors linked to depression. A noteworthy study in Poland examined the importance of
psychosocial factors in relation to depressive symptoms in patients with PSO (Wojtyna et al.,
2016). Certain factors addressed were gender, the age of onset of disease, the extent of disease,
perceived social support, subjective distress, and beliefs regarding the importance and influence
of appearance (Wojtyna et al., 2016). At the conclusion of the study, researchers found that
depressive symptoms and distress were higher in women than in men with women placing
greater value in appearances (Wojtyna et al., 2016). Despite these differences, psychological
distress was an important risk factor for depression in both men and women regardless of disease
severity (Wojtyna et al., 2016). Such findings have important implications for clinicians to take
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into consideration. Clinicians should assess patients with PSO for their subjective levels of
distress and recognize the role this chronic disease plays in psychological health (Wojtyna et al.,
2016).
Risk of the Additional Burden of Comorbidities in Patients with Psoriasis
Multiple comorbidities are associated with PSO including PsA, obesity, hypertension,
malignancies, metabolic syndrome, and cardiovascular disease (Feldman et al., 2017). Costs for
medical conditions associated with PSO are estimated at an additional $36.4 billion annually
(Feldman et al., 2017). Comorbidities can place significant distress among patients with PSO
adding to the potential burden of disease.
In efforts to better understand the additional burden of PsA as a comorbidity, one study
found that patients with PsA reported poor work productivity, worse pain and fatigue, and a
greater morbidity burden than those with PSO alone (Strober et al., 2017). It should also be noted
that in the same study 24% of patients with PSO and PsA reported depression as opposed to 16%
of those with PSO alone (Strober et al., 2017).
Increased risk for comorbidities in patients with PSO warrants greater medical
monitoring to ensure overall health and quality of life (Kimball et al., 2008). The National
Psoriasis Foundation suggests dermatologists must play an active role in educating patients on
the potential negative health effects of their PSO as they relate to other aspects of their health
and consider screening tests, preventative exams, and referrals for comorbidities (Kimball et al.,
2008).
Risk of Depression in Patients with Psoriasis
A link between PSO and depression exists throughout the literature. In a hospital-based,
case-control study in Iran, patients with PSO reported significantly higher degrees of depression
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than the control group, supporting a relationship between PSO and depression (Golpour et al.,
2012). Cohen, Martires, and Ho (2016) investigated the association of PSO and MDD in the U.S.
population and found that 16.5% of patients with PSO met the criteria for a diagnosis of MDD.
A meta-analysis study on the prevalence of depressive symptoms and clinical depression
in patients with PSO further supports the relationship between PSO and depression by revealing
that more than 10% of patients with PSO suffer from clinical depression and roughly 20% have
depressive symptoms (Dowlatshahi et al., 2014). Another more recent meta-analysis study
regarding the suicidality of patients with PSO found that compared to the general population,
patients with the disease are at increased risk for all aspects of suicidality (Singh et al., 2017).
In comparing depression in patients with other dermatologic diseases such a melanoma
and allergies, patients with PSO have an increased risk for psychiatric comorbidities and suicidal
ideations (Pompili et al., 2017). Of the patients with PSO, one study found that the risk for MDD
is significantly higher in women and patients with a severe clinical disease, comorbidities such
as PsA, and previous psychiatric conditions (Lamb et al., 2017). It should also be noted that
patients with PSO who are younger (age < 20) at the age of disease onset are often significantly
more depressed than patients with late-onset PSO (Remröd, Sjöström, & Svensson, 2013). The
literature supports that patients with PSO are at an increased risk for depression, and healthcare
providers should take this into consideration when caring for this population.
Implications for Depression Screening in Dermatology
The medical community generally recognizes the common occurrence of psychiatric
disorders among patients with physical diseases or chronic illnesses. Recently more studies have
demonstrated the prevalence of depression specifically among patients with dermatologic
diseases (AlShahwan, 2015). But though there are documented risks of depression for patients
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with dermatologic diseases, there is limited literature regarding the assessment of depression in
clinical dermatologic practice (McDonald et al., 2018). In the research studies that do address
depression screening in dermatology practice, assessment techniques included provider clinical
judgment, questionnaires, diagnostic criteria, and disease codes (Korman et al., 2016).
McDonald, Shelley, and Jaffernany (2018) acknowledge that patients and dermatologists could
benefit from a screening tool to identify secondary psychiatric conditions and recommend
standardized screening for depression and suicidal ideation.
While questionnaires are cited to be more commonly used in research studies, the most
commonly used method for assessing depression in patients with PSO in clinical practice is
clinician judgment (Dowlatshahi et al., 2014). The sensitivity and specificity of dermatologists’
clinical judgment for depression in patients with PSO has been found to be 60% and 21%
(Richards, Fortune, Weidmann, Sweeney, & Griffiths, 2004). The same study found that
agreement between dermatologists and patients with PSO regarding the presence of
psychological distress was low (Richards et al., 2004). Beyond this, the study also found that the
majority of times that patients were identified as being depressed, no further actions were taken
(Richards et al., 2004).
PHQ-9 For Depression Screening
Screening tools have been established as a cost-effective intervention to promote early
identification and treatment of depression used in a variety of healthcare settings (Jiao, Rosen,
Bellanger, Belkin, & Muennig, 2017; Wilkinson, Anderson, & Wheeler, 2017). This project
utilized the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a brief and useful
multipurpose instrument used to screen, diagnose, monitor, and measure depression severity
(Pfizer, 1999).
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While controversy exists over which depression screening tool is most reliable in clinical
practice, the PHQ-9 is a validated instrument in screening for MMD and depressive symptoms
(Suzuki, Kumei, Ohhira, Nozu, & Okumura, 2015). In one of the largest validation studies on the
PHQ-9, the sensitivity and specificity of the PHQ-9 was 74% and 91% (Arroll et al., 2010).
Compared to shortened versions of the PHQ-9, this tool is more specific for identifying
depression (Arroll et al., 2010). Unfortunately, a review of the literature revealed limited studies
on the use of depression screening tools specifically in dermatology practices. Though this gap in
the literature exists, the PHQ-9 has been used in studies for both depression and PSO (Lakshmy,
Balasundaram, Sarkar, Audhya, & Subramaniam, 2015). This notion highlights the need for
enhanced routine screening of patients with PSO as early detection of depression as a psychiatric
comorbidity (Lakshmy et al., 2015; Cohen et al., 2016).
Depression Screening Protocols
Screening patients for depression is important, but what providers do with positive
screenings after is just as important. To expedite the identification and treatment of depression
among different groups of patients, depression screening protocols are often used in practice
settings. One study examined the use of a depression screening protocol among patients with
acute stroke to determine if the protocol improved early detection and treatment of post-stroke
depression (McIntosh, 2017). The study utilized the PHQ-9 and found that the protocol improved
early detection and treatment of depression prior to hospital discharge for patients post-stroke
(McIntosh, 2017).
Another study examined the role of training in implementing a depression screening and
treatment protocol in outpatient internal medicine clinics (Loeb, Sieja, Corral, Zehnder, Guiton,
& Nease, 2015). Loeb et al. (2015) found that training attendance was associated with increased
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compliance with protocol procedures, highlighting the importance of training in the
implementation of practice changes. Considerations for this scholarly project recognize the value
of a screening protocol over a screening questionnaire alone and education on the use of the
protocol to promote appropriate use. Though this project did not specifically look at what
providers did with any positive depression screenings, the protocol did make recommendations
for follow up screenings based on individual PHQ-9 scores.
Conceptual Framework
The conceptual framework utilized in this EBP pilot project was the Iowa Model of
Evidence-Based Practice to Promote Quality Care (Iowa Model Collaborative, 2017). This
model is used throughout nursing research and is an effective model in leading an EBP change
(Hall & Roussel, 2014). The Iowa Model is a step-wise approach to addressing important steps
in a clinical question and determining evidence available to support clinical decisions (Hall &
Roussel, 2014). This model served as a map regarding the course of actions taken throughout the
implementation of this project to enhance provider assessment of depression in patients with
PSO.
Project Triggers
According to the Iowa Model, triggers must first be identified (Hall & Roussel, 2014).
The knowledge-focused trigger identified in this project was that patients with PSO are at a
significant risk for depression and suicidality (Singh et al., 2017). Many dermatology practices,
including the target private practice for this project, do not screen patients with PSO for
depression. This trigger presented an opportunity for improvement in comprehensive patient care
by assessing psychological health often not previously addressed.
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Organization Priority
This project addressed a priority for the private practice in which this project was
intended for implementation. The dermatology practice in question sees a variety of patients with
varying degrees of PSO on a daily basis. As a part of the mission statement, the practice strives
to offer patient-centered comprehensive care. Depression screening addresses psychological care
which is an important aspect of comprehensive care. Providing necessary supplies and educating
providers on the use of a depression screening protocol for patients with PSO may help the
practice to provide higher quality comprehensive care. The practice agreed that this project was
important and supported it.
Project Team and Research Assembly
The next steps of the Iowa Model include forming a team, assembling relevant research,
critiquing and synthesizing the research, and determining a sufficient base for the project (Hall &
Roussel, 2014). The team for this practice project consisted of one Doctor of Nursing Practice
(DNP) student or project leader, one graduate faculty advisor or project chair, and one provider
at the target practice. As outlined in the literature review, there was sufficient evidence for this
practice project and an identified need for depression screening tools in dermatology practice.
Though the use of depression screening tools in dermatology practice is limited, the screening
method chosen for this practice project has been used in such a setting, and clinical guidelines
call for a greater assessment of depression in patients with PSO.
Project Design, Piloting Change, and Evaluation
The fifth step of the Iowa Model calls for designing and piloting the practice change. This
EBP project involved implementing a depression screening protocol for patients with PSO at a
small private dermatology practice and educating providers on the use of the clinical tool. The
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dermatology providers caring for patients with PSO were the target population for this practice
project. Prior to piloting the practice change, the project leader developed an evaluation plan and
gathered baseline information on the average number of patients with PSO seen at the office as
well as provider use of depression screening pre-intervention. The promotion of practice change
adoption took place at one monthly provider meeting, and the DNP student was available
throughout the implementation phase by email or phone to answer questions from providers and
staff on the suggested practice change. Approximately two months after the suggested practice
change was introduced, the project leader gathered data on whether or not the intervention
improved the assessment of depression in patients with PSO. Whether or not this practice change
is appropriate for long-term adoption will depend on the providers’ perceptions of the usefulness
of the tool in practice and addressing any barriers to long-term implementation.
Methodology
Project Design
This was an EBP pilot project that consisted of implementing a depression screening
protocol for providers in dermatology to utilize in practice when caring for patients with PSO
(See Appendix F for depression screening protocol). This project took place over two months at
a private dermatology practice that sees approximately 15 patients with PSO per week. The
implemented screening protocol utilized one validated depression screening tool, the PHQ-9 (See
Appendix G for screening tool). As a quasi-experimental approach, the design of this project
allowed for the project leader to assess the impact of the intervention on provider assessment of
depression in patients with PSO by looking at pre- and post-intervention measures.
Because a screening protocol offers providers recommendations and interventions based
on patient outcomes, the project leader chose a screening protocol over the implementation of a
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depression questionnaire alone. This was an important consideration to help the project team
who recognized the gravity of depression and potential for positive screening warranting further
assessment. Though this project did not focus on how many positive screenings there were, a
plan on what to do if depression was identified was a significant consideration to the
implementation of this project at the target practice. A written document with suggestions for
how to address positive screenings and contact information for local mental health resources was
provided to each participating provider. Though the project leader offered suggestions, the
providers were able to address any positive depression screenings at their own discretion.
Adapted from Korman et al. (2016), the depression screening protocol encouraged
providers to screen patients with PSO at initial diagnosis or those patients previously diagnosed
with PSO that have never been screened for depression at the office. The original protocol
suggested the Patient Health Questionnaire-2 (PHQ-2) be used initially, which is a shortened
version of the PHQ-9. In efforts to streamline the depression screening protocol for the target
practice and for the purposes of this project, the project leader removed the PHQ-2 from the
protocol and recommended the PHQ-9 as the only screening questionnaire to be used.
According to the protocol, patients who scored less than or equal to ten on the PHQ-9
should be recommended for repeat depression screening in one year (Korman et al., 2016). For
those patients who scored between eleven and fourteen, a repeat PHQ-9 was recommended at the
following visit (Korman et al., 2016). Lastly, those patients who scored greater than or equal to
fifteen were recommended for referral for psychiatric evaluation with repeated PHQ-9 screening
suggested at the next office visit (Korman et al., 2016). Though patients who scored fifteen or
greater were recommended for referral based on the protocol, providers were made aware that
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any patients identified with depression could also be referred and that referrals were ultimately
up to the discretion of the individual provider.
This project did not address specific patients directly. The intervention did not look at
how many positive depression screens there were or how treatment was carried out, but rather
how having this protocol available in practice and educating providers on the use of the protocol
impacted provider assessment of depression in patients with PSO.
Measurable Outcomes
Measurable outcomes were important to this EBP project as they helped to define how
the depression screening protocol and provider education impacted the assessment of patients
with PSO for depression at the project site. The measurable outcomes for this project were the
number of patients with PSO screened for depression compared to the total number of patients
with PSO seen at the office pre-and post-implementation of the depression screening protocol.
The time frame of interest was a 30-day period before the intervention and a 30-day period after
the intervention. The number of depression screenings documented and the total number of
patients with PSO seen during the pre-intervention 30-day time frame by all participating
providers served as the before measures. The number of depression screenings documented and
the total number of patients with PSO seen during the post-intervention 30-day time frame by the
participating providers served as the after measures.
Setting
The setting for this EBP project was a private dermatology practice caring for patients
with a variety of dermatologic needs. The practice strives to provide comprehensive and quality
healthcare which aligned with this project’s aim. The organizational structure of the practice
includes physician practice owners, managers, providers, a nurse, clinical assistants, and non-
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clinical staff. The clinical assistants and the nurse involved in direct patient care likely played an
important role in providing patients with depression screening questionnaires based on identified
depression screening needs as determined by the providers. The support of practice
administrators was crucial to the success of the project implementation.
Population
The target subjects for this EBP project were nine dermatology providers within the same
dermatology practice including four physicians and five advanced practice providers. The
advanced practice providers consisted of four physician assistants and one nurse practitioner.
Though there were nine providers at the practice, two physicians and one physician assistant
were excluded from this project as they do not manage care for patients with PSO but instead
work in surgical or aesthetic areas of the practice. Each of the other six providers serve different
roles within the practice but all six provide care for patients with PSO, some more than others.
Ethical Considerations
For the protection of subject rights, no personal information regarding the participating
providers or place of practice was disclosed. The participating providers were also not penalized
for choosing not to screen patients with PSO for depression. Though the office also cares for
pediatric patients, the project leader told providers to avoid screening anyone under than age of
18 using the protocol provided, and no data was collected from patients under the age of 18 or
over the age of 90. Providers were not compensated for participating in the project; however, the
project leader provided a meal to the practice at the conclusion of the project in gratitude for
provider and staff participation.
The project leader has completed research ethics training to ensure protection of human
subjects (see Appendix C for CITI certificate). The committee-approved project proposal was
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submitted to Liberty University’s (LU’s) Institutional Review Board (IRB) and received
exemption from further review as this project fell under an exemption for involving the
collection of information in such a manner by the investigator that subjects cannot be identified,
directly or through identifiers linked to the subjects (see Appendix B for IRB approval
documentation). There was no IRB at the project site. Though LU’s IRB waived formal written
consent from individual providers for this project, the project leader obtained written consent
from the practice administration for project implementation and use of the electronic medical
record (EMR) for data collection (see Appendix D for site approval).
Data Collection
The project leader performed retrospective chart reviews for a 30-day period four weeks
before the intervention and four weeks after the intervention to obtain data for this project. The
project leader reviewed charts for patients with a diagnosis of PSO as well as the documentation
of depression screening in the form of the PHQ-9. The number of patients with PSO who were
seen within the 30-day time frames pre- and post-intervention and the number of depression
screenings, in the form of the PHQ-9, were recorded.
Though the project leader performed chart reviews on patients throughout this project,
the leader did not utilize any identifying patient or provider information. As mentioned, the
primary focus of this project was whether or not provider assessment of depression was
enhanced with the implementation and education of a depression screening protocol rather than
how this screening would affect patients with PSO. The project leader reviewed charts during
data collection based on those patients with PSO cared for by participating providers, equal or
greater than 18 years old and equal or less than 90 years old, and those seen at the office within a
30-day period prior to and following the intervention. The data was grouped as “pre-
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intervention” or “post-intervention” according to the date of the visit and “yes” or “no” for
whether or not depression screening was documented. This data was later coded for statistical
analysis as the following: “pre-intervention” = 1, “post-intervention” = 2, “no” = 1, and “yes”
=2.
There was no personal health protected information written or stored outside of the EMR
that was used to track the number of patients seen with PSO and the number of depression
screenings documented. The data collection was reserved to the project leader who upheld
compliance with the Health Information Portability and Accountability Act (HIPAA). The data
was kept on a password-protected computer only accessible to the project leader in a Microsoft
Excel® spreadsheet. This spreadsheet will be kept for three years following the completion of
the project. After three years, the electronic documents will be placed into the computer trash bin
and permanently removed from the bin in order to support further privacy.
Tools
The main tools necessary for this EBP project were the depression screening protocol and
embedded screening questionnaire, the PHQ-9. The project leader gave the providers copies of
the tools and placed more copies in most exam rooms within a file folder under a tab labeled
“Depression Screening.” Along with these tools, the project leader also provided laminated
copies of the suggested course of action for patients identified with depression and handouts on
how to interpret PHQ-9 results to the participating providers.
In order to complete the chart reviews, the project leader used the practice’s established
EMR. Sorting tools within the office’s established EMR allowed for the identification of patients
seen within a specified time frame. The project leader reviewed charts for all participating
providers during each 30-day pre- and post-intervention period for a diagnosis of PSO and
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whether or not depression screening was documented. Microsoft Excel® was the data collection
tool used to manually track the date of visits for patients with PSO and whether or not screening
was documented in the EMR. This tool was accessed on a password protected computer only
accessible to the project leader.
Intervention
The intervention for this EBP project was the depression screening protocol in
combination with education to providers on use of the screening tool in practice (See Appendix F
for depression screening protocol). This protocol was adapted and modified from an article on
the evaluation and management of depression in patients with PSO (Korman et al., 2016). The
tool or questionnaire utilized in the depression screening protocol, the PHQ-9, is publicly
available for providers to use in practice as well as in this project (Pfizer, 1999).
The intervention, including the depression screening protocol and education to providers
on the use of the protocol, was delivered at one monthly provider meeting. The project leader
educated providers on the prevalence of depression among patients with PSO, the depression
screening protocol itself including the embedded PHQ-9, and where to find resources for this
protocol at the office. In addition to these topics, the project leader gave providers the suggested
course of action to take for any patients identified with depression and contact information for
local mental health resources. The day following the provider meeting marked the introduction
of the protocol in practice.
Timeline of Project Phases
Preparation. The preparation for this project consisted of identifying the problem-focused
triggers, determining if the topic was a priority for the organization, forming a team, assembling
and synthesizing research, and determining if there was sufficient research to base the practice

DEPRESSION SCREENING FOR PATIENTS WITH PSORIASIS

36

change. The steps of this project’s preparation reflected the conceptual framework used, the Iowa
Model of Evidence Based Practice. The activities that occurred during the preparation phase
included the following:
•

On September 4th, 2017, the project leader presented the project proposal to a practice owner
and key stakeholder.

•

On December 20th, 2017, the project leader delivered the project proposal to the project chair
and approval was given with minimal edits.

•

On April 5th, 2018, the project leader submitted the project proposal to LU’s IRB.

•

On May 11th, 2018, LU’s IRB approved the project proposal.

•

On June 1st, 2018, the project leader formed the project team.
Implementation. After preparation and according to the conceptual framework, the

implementation phase consisted of the introduction of the depression screening protocol and
education to the providers on the use of the protocol. This also consisted of providing necessary
supplies for the providers to use for the depression screening protocol in practice. The activities
that occurred during this stage included:
•

On June 7th, 2018, the project leader placed copies of the depression screening protocol,
PHQ-9’s, and other protocol documents in most exam rooms for the providers to use or
within the shared work areas.

•

On June 7th, 2018, the project leader delivered the intervention at one monthly provider
meeting.

•

June 8th, 2018, marked the introduction of the protocol in practice.

•

On July 8th, 2018, the 30-day window period post-intervention began.
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August 1st – August 6th, 2018, the project leader performed chart reviews for pre- and postintervention.

•

On August 6th, 2018, the 30-day window period post-intervention ended.
Evaluation. Following the Iowa Model of EBP, the project leader evaluated the

intervention to determine if a change in practice occurred. The activities that occurred during the
evaluation stage included the following:
•

On August 6th, 2018, the project leader completed all pre-and post-intervention chart reviews.

•

On August 7th, 2018, the project leader completed the data analysis.

•

On October 1, 2018, the project leader will disseminate project results to the providers at the
practice.

Data Analysis
The data analysis for this EBP project took place using IMB® Statistical Package for the
Social Sciences® (SPSS®), Version 25.0, to generate statistical and descriptive results. Because
the data was nominal in nature, the data collected for this project best fit statistical testing
utilizing the Fisher’s exact test of independence because of the small sample size (Rao, 2017).
This nonparametric statistical test is used when one wants to determine if the proportions for one
variable are different among values of the other variable (Rao, 2017). The project leader
categorized the data as “pre-intervention” or “post-intervention” and as “no” or “yes” for
whether or not depression screening was documented. For analysis purposes, the project leader
coded the data in order to run the statistical test (“pre-intervention” = 1, “post-intervention” = 2,
“no” = 1, and “yes” = 2). For the Fisher’s Exact test, the null hypothesis was that there was no
change in the number of depression screenings documented for patients with PSO from preintervention to post-intervention (H0: p1 = p2). The alternative hypothesis was that there was an
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increase in depression screenings documented for patients with PSO from pre-intervention to
post-intervention (H1: p1 < p2). An alpha of 0.05 was used. For descriptive statistics, the project
measures were reported as ratios and percentages for comparison of pre- and post-intervention
outcomes. Besides SPSS®, the project leader used Microsoft Excel® to generate figures and a
table for the visualization of results pre- and post-intervention.
Feasibility Analysis
The costs of this EBP project were minimal. The costs included office supplies and
printing for the depression screenings tools including labeled folders, laminated copies of the
depression screening protocol, PHQ-9 interpretation handout, and suggested course of action,
and paper copies of the PHQ-9’s that were placed in exam rooms. The total costs for the office
supplies and printing was approximately $150. The project leader provided education to the
providers at no charge and collected data utilizing an already established EMR. This project was
very feasible for the dermatology practice and this aided in the implementation of the project.
Currently depression screening is reimbursed in primary care on an annual basis
averaging just under $20 per screening per person (Savoy & O'Gurek, 2016). Evidence-based
guidelines recommend depression screening for all patients with PSO (Burden et al., 2010).
Unfortunately, reimbursement for depression screenings in specialty care offices is still lacking,
offering an opportunity for the future in policy change to promote quality comprehensive care.
Though the project was not targeted to increase financial gain for the practice at this time, the
EBP project may offer other beneficial aspects including improvement in mental health
screenings among patients with PSO, enhancements in providing comprehensive care, and
greater congruency to EBP guidelines for screening depression among patients with PSO.
Financial benefits may be seen in the future if the providers utilize depression screening long
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term, or the practice considered utilizing depression screening as part of merit-based incentive
payment programs. Overall, the potential benefits of this project outweigh the minimal costs.
Results
The project leader utilized statistical testing and descriptive statistics to demonstrate the
results of this project. Based on the pre-intervention retrospective chart reviews, there were a
total of 57 patients with PSO seen at the office within the 30-day pre-intervention time frame by
the participating providers. Of these patients with PSO seen at the office pre-intervention,
providers documented 0 PHQ-9 depression screenings in the EMR. The percentage of patients
with PSO screened for depression in practice pre-intervention was 0% (Figure 1).

Pre-Intervention Depression Screening
for Patients with Psoriasis

0%

100%

Patients screened

Patients NOT Screened

Figure 1. Pre-Intervention Depression Screening for Patients with Psoriasis
Based on the post-intervention retrospective chart reviews, there were a total of 45
patients with PSO seen at the office within the 30-day post-intervention time frame by
participating providers. Of these patients with PSO seen at the office post-intervention, providers
documented 7 PHQ-9 depression screenings in the EMR. The percentage of patients with PSO
screened for depression in practice post-intervention was 15.6% (Figure 2).
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Post-Intervention Depression Screening
for Patients with Psoriasis
15.6%

84.4%

Patients screened

Patients NOT Screened

Figure 2. Post-Intervention Depression Screening for Patients with Psoriasis
In order to evaluate whether this change in screening was statistically significant, the
project leader applied the Fisher’s exact test to the data. SPSS® results for the Fisher’s exact test
generated a pre- and post-intervention cross tabulation and a p-value of 0.002 (Table 1).
Table 1
Pre- and Post-Intervention Cross Tabulation and Fisher’s Exact Test Results
Depression Screening?

Pre- Intervention

Post- Intervention

P-value

No

Yes

Total

Count

57

0

57

Percentage (%)

100.0%

0.0%

100%

Count

38

7

45

Percentage (%)

84.4%

15.6%

100%

Fisher’s Exact

0.002
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Discussion
By looking at the results from this EBP project, the number of documented depression
screenings increased from pre- to post-intervention. Based on the results that 0/57 of the patients
with PSO were screened for depression prior to the intervention and 7/45 were screened after the
intervention, there was a 15.6% increase in the overall pre-intervention and post-intervention
measures for this project.
Considering the Fisher’s exact test with an alpha of 0.05, a p = 0.002 caused for the
rejection of the null hypothesis in favor of the alternative. The null hypothesis stated that no
change in the number of depression screenings documented for patients with PSO from preintervention to post-intervention would occur (H0: p1 = p2). The alternative hypothesis stated an
increase in depression screenings documented for patients with PSO from pre-intervention to
post-intervention would occur (H1: p1 < p2). Based on the p-value of 0.002 generated from the
Fisher’s exact test and that p = < 0.05, the null hypothesis was rejected and the alternative
accepted, demonstrating that the change in depression screening was statistically significant.
The ultimate goal of this project was to encourage practice change. The results from this
project demonstrated statistical and clinical improvement in depression screening for patients
with PSO at the target practice. This answers the project’s clinical question supporting that the
implementation of a screening protocol and education to the providers on the use of the protocol
did improve the assessment of depression in patients with PSO. Various unforeseen factors arose
during the implementation of this project and in subsequent paragraphs, the project leader
considers limitations of this project as well as recommendations for future implementation and
research considerations.
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Project Limitations
There were limitations to this project. First, the sample size for this project was very
small totaling only six participating providers who cared for 102 patients with PSO during the
project’s data collection window: 57 pre-intervention and 45 post-intervention. Because the
project’s sample size was small, the project design utilized convenience sampling, and the
project leader did not collect data randomly, the results from this project cannot be generalized.
Second, shortly after the introduction of the protocol in practice, the practice’s
administration placed a hold on providers administering the depression screenings as the office’s
legal advisors considered any legal barriers to implementation. This meant the first four weeks
following the introduction of the protocol in practice could not be used for data collection as
originally designed, therefore, the providers may have forgotten some of the content provided in
the intervention. Providers were notified shortly after the administration agreed to allow the
project to proceed, but the intervention was not repeated which may have impacted provider
screening rates.
Another limitation of the project is that the project did not address how providers adhered
to any follow-up screening based on the individual PHQ-9 results and protocol
recommendations. The project looked at a 30-day period after the protocol was introduced to see
if patients with PSO were screened for depression utilizing the PHQ-9. Documentation of
depression screening did not require any mentioning of follow up screening. Further studies
utilizing a similar depression screening protocol should take place over the course of a longer
time period in order to study adherence to follow-up screening recommendations on a long term
basis.
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The final limitation for this discussion was how the data was collected. The data
collection was reserved for the project leader who manually reviewed charts from visits during
two 30-day time frames for the participating providers recognizing a diagnosis of PSO and
whether or not depression screening was documented. The project leader may have missed a
patient with a diagnosis for PSO or documentation of depression screening. Sorting tools in an
established EMR may be helpful for similar studies or projects in the future in order to more
efficiently and effectively review documentation for depression screenings.
Significance and Implications for Practice
The results of this project have important implications for the future in relation to
depression screening for patients with PSO in a dermatology care setting and specifically at the
project site. While statistically significant improvement in provider screening rates postintervention was noted, the project did not address whether or not the screenings were from one
or multiple providers. It would be beneficial in the future to understand why, if any, providers
opted not to screen patients for depression in practice. While 15.6% was an improvement in the
overall percentage of patients with PSO that were screened for depression from pre-intervention
results, it would also be beneficial to understand why 84.4% were not screened for depression.
One could hypothesize some barriers including time constraints, provider experience with
screening for depression, visit priorities, length of the PHQ-9, and many others, but without
studying provider perceptions of depression screening for this patient population in a
dermatology care setting, no inferences can be made.
The project leader recommends future projects or studies to gather insight on the barriers
to the implementation of depression screening for patients with PSO in a dermatology. Limiting
barriers to implementation specifically in a dermatology care setting may help to enhance
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provider assessment of depression in patients with PSO in the future. Another recommendation is
to utilize a shorter version of the PHQ-9 in the screening protocol, such as the PHQ-2. Screening
protocols incorporating the PHQ-2 do exist and may offer quicker methods to screening for
depression in dermatology practice (Korman et al., 2016; McDonald, Shelley, & Jafferany,
2018).
The fact that depression screening improved 15.6% post-intervention is important to
acknowledge, especially when considering implications for practice. Providers did not previously
screen patients with PSO for depression at the target practice. After the intervention, providers
engaged in screening which means they likely found screening important or valuable in a clinical
setting and potentially previously lacked the awareness of the risk of depression in this patient
population or lacked the tools to screen for depression in dermatology practice. With that being
said, one must consider how many other dermatology care providers do not screen patients with
PSO for depression and the importance of spreading awareness for this intervention as well as
tools for depression screening in other similar settings.
Sustainability
This project demonstrated a change in practice from pre- and post-intervention. Whether
this change in practice will be adopted long term will depend on addressing any barriers to the
implementation of the protocol at the practice site. This project could be sustainable long term,
as the costs for implementation are low and the potential for changes to reimbursement for
depression screening in the future could benefit the practice financially. Furthermore, the project
leader chose to leave screening materials with the office in hopes that providers would continue
to utilize the recommended protocol. However, it will be ultimately up the practice’s
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administration and the providers as to whether or not they choose to continue to screen patients
with PSO for depression in practice.
Dissemination Plan
The findings from this project will be disseminated to the practice providers involved in
this project with a report on the results, the lessons learned, and suggestions for enhanced
depression screening for patients with PSO. The project leader also seeks to submit a manuscript
based on this project for publication to a nursing journal specific to dermatology. The project
leader will also upload this project to the LU’s Digital Commons where it can be accessed online
around the world. The project leader will continue to seek opportunities to share this project in
the future and information regarding the importance of assessing patients with PSO for
depression in practice.
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participants
were not
randomized

(Y) Offers
insights into
real-world
implementation
of
screening/treatm
ent for
depression

N/A

Level
VII

Expert
opinion –
lowest level
of evidence

(Y) – Suggests
that
dermatologists
and patients can
benefit from
screening tool to
identify
emotional
distress

Implementation
of a EBP
depression
screening and
treatment
protocol
improved early

Level
III

Retrospective
chart review
design, short
implementati
on phase

(Y) Depression
screening
protocols can
help with early
diagnosis and
treatment of
depression
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protocol in
improving
early
detection and
treatment of
PSD
Assess
effects of
psoriasis on
QoL, selfesteem, and
body image.

92 patients
with
psoriasis
and 98
control
participants

Examine the
risk of
suicide and
stressful life
events in a
sample of
patients with
skin disease

242
dermatolog
y patients,
112
psoriasis, 77
melanoma,
53 chronic
allergies

60
detection and
treatment of
depression

Sociodemographic
characteristics
were assessed
with PASI
scores, results
from three
surveys on
quality of life,
body image,
and selfesteem were
evaluated
Pts were
administered
the MINI
International
Neuropsychiat
ric Interview,
Hamilton
Depression
Rating Scale,
Hamilton
Anxiety
Rating Scale,
and the
ColumbiaSuicide
Severity
Rating Scale

Self-esteem,
body image,
and quality of
life was found
to be more
negatively
affected in
psoriasis
patients over
control

Level
III

Duration of
illness,
Socioeconomic
status and
income were
not
accounted for

(Y) links
psoriasis to
causing
psychosocial
problems

Patients with
psoriasis were
more likely to
have a history
of psychiatric
disorders
compared to
patients with
allergies and
reported past
suicidal
ideation as
compared to
those with
melanoma and
allergies

Level
III

Not provided

(Y) Patients
affected by
psoriasis have
an increased risk
of psychiatric
comorbidities
and suicidal
ideation
compared to
those who have
other
dermatological
disorders
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Determine
whether
patients with
early-onset
psoriasis
differ
psychologica
lly from
patients with
late-onset
psoriasis,
regarding
personality
traits,
anxiety and
depression
Examine the
level of
agreement
between
dermatologis
ts and
patients with
psoriasis as
to the
presence of
clinically
significant
psychologica
l distress
A perform a
systematic
review and
metaanalysis that
elucidates
the
relationship
between
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101
consecutivel
y recruited
outpatients
with
psoriasis

A descriptive
crosssectional
study was
conducted

Early-onset
psoriasis (age <
20 years) were
significantly
more anxious
and depressed
than patients
with late-onset
psoriasis.

Level
VI

A selection
bias could be
contributing
to results
speculating
that
individuals
with strong
traits of
detachment
would be less
likely to seek
medical care

(Y) Supports
early diagnosis
and recognition
of depression
and screening
early on in
diagnosis

Forty-three
consultation
s between
dermatologi
sts and
patients
with
psoriasis
were
assessed

Consisted of
two
assessments
1) for patients
1) for
providers to
measure
anxiety and
depression

The level of
agreement
between patient
rating and
dermatologist
rating as to the
presence of
anxiety or
depression was
low

Level
IV

Small sample
size,
underestimati
on of
prevalence of
depression

(Y) Highlights a
number of areas
for improvement
in the
psychological
management of
patients with
psoriasis.

18 studies
were
identified

Systematically
searched the
PubMed,
EMBASE,
PsycINFO,
and Cochrane
databases.
Searched
literature
published

Subgroup
analysis
showed that
patients with
psoriasis were
more likely to
attempt
suicides and
complete
suicide. Those

Level I

There were
few studies
examining
suicidality in
conjunction
with
psoriasis
severity

(Y) Patients
with psoriasis
have a
significantly
higher
likelihood of
suicidal
ideation, suicide
attempts, and
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Characterize
the PsO
patients with
psoriatic
arthritis
(PsA) and
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association
of outcomes
with PsA in
Corrona, a
prospective
cohort of
patients with
PsO.

Adult
patients
enrolled in
Corrona as
of May 31,
2016
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Examine the
utility of
PHQ-9 and
PHQ-2

574 patients
for PHQ-9
and 521
patients for
PHQ-2

between 1946
and 2017.
Applying the
Preferred
Reported
Items for
Systematic
Reviews and
Meta
Analyses
guidelines
Multivariate
logistic
regression
was
conducted to
examine the
association of
other
comorbidities
with presence
of PsA,
adjusted for
age, gender,
body mass
index (BMI)
and disease
duration of
PsO.

Administered
PHQ-2 and 9

62
younger and
who psoriasis
was more
severe were
found to be at
a greater risk.

Psoriasis
patients with
PsA had similar
disease
severity,
however,
reported poorer
work
productivity,
worse pain and
fatigue and
were more
likely to have
comorbidity
burden
compared to
those who did
not have
concurrent PsA
at enrollment in
to the registry
Forty-two
patients were
diagnosed with
major
depressive
disorders

completed
suicides.

Level
VI

Regression
study

(Y) Increased
burden of
disease in
patients with
PsA
comorbidity

Level
IV

Administered
in primary
care only

(Y) The PHQ-9
and PHQ-2 were
useful
instruments for
screening for
major
depressive
disorders.
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To examine
psychosocial
issues and
relationship
to depression
symptoms in
patients with
psoriasis

219 patients
with
psoriasis
ages 18-70
yrs old

Depression,
appearance,
social support,
and distress
surveys
utilized, BSA
index for
severity of
psoriasis.
Multivariate
logistic
regression
analysis was
performed on
results.

63
49.8% of
participants had
probable
depression;
among those,
11.9%
presented
severe, 18.2%
moderate and
19.7% mild
depressive
symptoms. as
defined nearly
21% of
respondents
reported
suicidal
thoughts.
symptoms and
distress were
significantly
higher in
women than in
men

Level
III

Some
participants
were from a
psoriasis
association,
study was
crosssectional

(Y) High rates
of psychological
impairments in
patients with
psoriasis
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IRB Approval Documentation

May 11, 2018
Marlee Bryant
IRB Exemption 3247.051118: Implementation of a Screening Protocol to Improve Provider
Assessment of Depression in Patients with Psoriasis
Dear Marlee Bryant,
The Liberty University Institutional Review Board has reviewed your application in accordance
with the Office for Human Research Protections (OHRP) and Food and Drug Administration
(FDA) regulations and finds your study to be exempt from further IRB review. This means you
may begin your research with the data safeguarding methods mentioned in your approved
application, and no further IRB oversight is required.
Your study falls under exemption category 46.101(b)(4), which identifies specific situations in
which human participants research is exempt from the policy set forth in 45 CFR 46:101(b):
(4) Research involving the collection or study of existing data, documents, records, pathological specimens,
or diagnostic specimens, if these sources are publicly available or if the information is recorded by the
investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the
subjects.

Please note that this exemption only applies to your current research application, and any
changes to your protocol must be reported to the Liberty IRB for verification of continued
exemption status. You may report these changes by submitting a change in protocol form or a
new application to the IRB and referencing the above IRB Exemption number.
If you have any questions about this exemption or need assistance in determining whether
possible changes to your protocol would change your exemption status, please email us at
irb@liberty.edu.
Sincerely,

G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
The Graduate School

Liberty University | Training Champions for Christ since 1971
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Depression Screening Protocol

Adapted and modified from:
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Appendix G
Patient Health Questionnaire-9

No permission required to reproduce, display, or distribute. Adapted from patient health
questionnaire (PHQ) screeners. Retrieved from http://www.phqscreeners.com/sites/g/files/g
10016261/f/201412/PHQ-9_English.pdf
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